<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735527</url>
  </required_header>
  <id_info>
    <org_study_id>INLOR</org_study_id>
    <nct_id>NCT00735527</nct_id>
  </id_info>
  <brief_title>Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children</brief_title>
  <acronym>INLOR</acronym>
  <official_title>Intra-Nasal vs. Intra-Venous Lorazepam for Control of Acute Seizures in Children: Prospective Open Labeled Randomized Equivalence Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Status epilepticus (SE) is a common pediatric emergency which is potentially life-threatening
      and requires rapid termination. Early and effective treatment is essential to prevent the
      morbidity and mortality associated with prolonged convulsive SE. Lorazepam is the standard of
      care for control of SE when administered by intra-venous (IV) route. The investigators intend
      to compare efficacy and adverse effect profile of intra-nasal vs. intravenous routes of
      administration of lorazepam. In resource poor settings, sometimes trained personnel or
      appropriate equipment for intra-venous cannulation is not available. Alternate routes of
      administration, if shown equivalent to conventional IV route, will be very useful in such
      settings or for out of hospital management of seizures in children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cessation of all clinical seizure activity within 10 min of drug administration</measure>
    <time_frame>10 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistent cessation of seizure activity for 1 hr</measure>
    <time_frame>1 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients requiring rescue medication within 1 hr</measure>
    <time_frame>1 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve intra-venous access after arrival in casualty</measure>
    <time_frame>minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from drug administration to termination of seizure(s)</measure>
    <time_frame>minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of hypotension (fall of &gt;/= 20 mmHg systolic and/ or &gt;/= 10 mmHg diastolic pressure) within 1 hr of drug administration</measure>
    <time_frame>1 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of significant respiratory depression requiring assisted ventilation</measure>
    <time_frame>1 hr</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Status Epilepticus</condition>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-nasal lorazepam 0.1 mg/kg (max 4 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-venous lorazepam 0.1 mg/kg (max 4 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam</intervention_name>
    <description>Intra-nasal 0.1 mg/kg (maximum 4 mg) once</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam</intervention_name>
    <description>Intra-venous 0.1 mg/kg (maximum 4 mg) once</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children presenting convulsing to the pediatric emergency or developing seizure while
             in casualty

          -  Age 6-14 years

        Exclusion Criteria:

          -  Known hypersensitivity to any benzodiazepine

          -  Child has received any parenteral anti-convulsant within 1 hr prior to enrollment

          -  Presence of severe cardio-respiratory compromise or cardiac arrhythmias

          -  Presence of upper respiratory tract infection

          -  Presence of basal skull fracture causing cerebro-spinal fluid (CSF) rhinorrhea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2008</study_first_posted>
  <last_update_submitted>May 4, 2009</last_update_submitted>
  <last_update_submitted_qc>May 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ravindra Arya</name_title>
    <organization>All India Institute of Medical Sciences</organization>
  </responsible_party>
  <keyword>seizures</keyword>
  <keyword>status epilepticus</keyword>
  <keyword>lorazepam</keyword>
  <keyword>intra-nasal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

